Literature DB >> 28116808

Lipocalin-2 expression and serum levels as early predictors of type 2 diabetes mellitus in obese women.

Nearmeen M Rashad1, Amal S El-Shal2, Rasha L Etewa2, Fady M Wadea1.   

Abstract

Obesity and diabetes are increasing in epidemic proportions globally. Lipocalin-2 (LCN-2) is an inflammatory adipocytokine and obesity-related marker of low-grade inflammation. We aimed to investigate, for first time, the possible role of LCN-2 expression and serum levels in prediction of impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) among obese Egyptian women. This study included 188 obese women and 180 controls. Obese women were subdivided into three subgroups according to their fasting blood glucose, normal glucose tolerance (NGT), IGT and T2DM. Circulating LCN-2 expression levels were determined by real time polymerase chain reaction. Serum LCN-2 concentrations were assessed by ELISA. Our findings revealed that LCN-2 expression and serum levels were higher in obese women compared to lean controls. They were higher in IGT and T2DM obese cases than in NGT obese women. Receiver operating characteristic analyses revealed that LCN-2 expression level was a useful biomarker discriminating IGT from NGT and T2DM from IGT obese women (AUC were 0.735 and 0.740, respectively). It was an independent predictor of IGT and T2DM among obese women. Serum LCN-2 level was a useful biomarker discriminating IGT from NGT and T2DM from IGT obese women (AUC were 0.705 and 0.728, respectively). It was independent predictor of T2DM without predicting IGT among obese women. The power of combined LCN-2 serum levels and expression in discriminating between IGT from NGT and T2DM from IGT obese women was high (AUC = 0.717 and 0.741, respectively). In conclusion, LCN-2 expression and serum levels could discriminate IGT from NGT and T2DM from IGT obese women and early predicting T2DM among obese women. While, LCN-2 expression level was the independent predictor of IGT in obese women. Combination of both LCN-2 expression and serum levels improved their diagnostic value in early detection of IGT and T2DM among obese women.
© 2017 IUBMB Life, 69(2):88-97, 2017. © 2017 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  impaired glucose tolerance; lipocalin-2; obesity; real time-polymerase chain reaction; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 28116808     DOI: 10.1002/iub.1594

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  14 in total

1.  The relationship among serum lipocalin 2, bone turnover markers, and bone mineral density in outpatient women.

Authors:  Dong-Mei Liu; Hong-Yan Zhao; Lin Zhao; Min-Jia Zhang; Ting-Ting Liu; Bei Tao; Li-Hao Sun; Jian-Min Liu
Journal:  Endocrine       Date:  2018-01-02       Impact factor: 3.633

Review 2.  Lipocalin-2 expression and function in pancreatic diseases.

Authors:  Kristyn Gumpper; Andrew William Dangel; Valentina Pita-Grisanti; Somashekar G Krishna; Luis F Lara; Thomas Mace; Georgios I Papachristou; Darwin L Conwell; Phil A Hart; Zobeida Cruz-Monserrate
Journal:  Pancreatology       Date:  2020-01-07       Impact factor: 3.996

3.  Lipocalin 2 as a Putative Modulator of Local Inflammatory Processes in the Spinal Cord and Component of Organ Cross talk After Spinal Cord Injury.

Authors:  Victoria Behrens; Clara Voelz; Nina Müller; Weiyi Zhao; Natalie Gasterich; Tim Clarner; Cordian Beyer; Adib Zendedel
Journal:  Mol Neurobiol       Date:  2021-08-21       Impact factor: 5.590

4.  Impact of Zinc to Copper Ratio and Lipocalin 2 in Obese Patients Undergoing Sleeve Gastrectomy.

Authors:  Hala M Demerdash; Ahmed A Sabry; Omar E Arida
Journal:  Biomed Res Int       Date:  2022-06-10       Impact factor: 3.246

5.  Lipocalin-2: a role in hepatic gluconeogenesis via AMP-activated protein kinase (AMPK).

Authors:  W-X Sun; K Lou; L-J Chen; S-D Liu; S-G Pang
Journal:  J Endocrinol Invest       Date:  2021-01-09       Impact factor: 4.256

6.  Lipocalin 2 Does Not Play A Role in Celastrol-Mediated Reduction in Food Intake and Body Weight.

Authors:  Xudong Feng; Dongxian Guan; Thomas Auen; Jae Won Choi; Mario Andres Salazar-Hernandez; Farhana Faruk; Kyle D Copps; Umut Ozcan
Journal:  Sci Rep       Date:  2019-09-05       Impact factor: 4.379

Review 7.  Cytokines and Abnormal Glucose and Lipid Metabolism.

Authors:  Jie Shi; Jiangao Fan; Qing Su; Zhen Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-30       Impact factor: 5.555

8.  Sex-specific metabolic functions of adipose Lipocalin-2.

Authors:  Karthickeyan Chella Krishnan; Simon Sabir; Michaël Shum; Yonghong Meng; Rebeca Acín-Pérez; Jennifer M Lang; Raquel R Floyd; Laurent Vergnes; Marcus M Seldin; Brie K Fuqua; Dulshan W Jayasekera; Sereena K Nand; Diana C Anum; Calvin Pan; Linsey Stiles; Miklós Péterfy; Karen Reue; Marc Liesa; Aldons J Lusis
Journal:  Mol Metab       Date:  2019-09-27       Impact factor: 7.422

Review 9.  The Interplay Between Bone and Glucose Metabolism.

Authors:  Cristiana Cipriani; Luciano Colangelo; Rachele Santori; Mario Renella; Monia Mastrantonio; Salvatore Minisola; Jessica Pepe
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

10.  Serum Levels and Placental Expression of NGAL in Gestational Diabetes Mellitus.

Authors:  Xiaoqian Yin; Yan Huo; Li Liu; Yixing Pan; Suxin Liu; Runfang Wang
Journal:  Int J Endocrinol       Date:  2020-01-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.